Overexpression of REST Represses the Epithelial-Mesenchymal Transition Process and Decreases the Aggressiveness of Prostate Cancer Cells.
Sebastián IndoOctavio Orellana-SerradellMaría José TorresEnrique A CastellónHéctor R ContrerasPublished in: International journal of molecular sciences (2024)
The RE-1 silencing transcription factor (REST) is a repressor factor related to neuroendocrine prostate cancer (PCa) (NEPC), a poor prognostic stage mainly associated with castration-resistant PCa (CRPC). NEPC is associated with cell transdifferentiation and the epithelial-mesenchymal transition (EMT) in cells undergoing androgen deprivation therapy (ADT) and enzalutamide (ENZ). The effect of REST overexpression in the 22rv1 cell line (xenograft-derived prostate cancer) on EMT, migration, invasion, and the viability for ENZ was evaluated. EMT genes, Twist and Zeb1, and the androgen receptor (AR) were evaluated through an RT-qPCR and Western blot in nuclear and cytosolic fractions of REST-overexpressing 22rv1 cells (22rv1-REST). The migratory and invasive capacities of 22rv1-REST cells were evaluated via Transwell ® assays with and without Matrigel, respectively, and their viability for enzalutamide via MTT assays. The 22rv1-REST cells showed decreased nuclear levels of Twist, Zeb1, and AR, and a decreased migration and invasion and a lower viability for ENZ compared to the control. Results were expressed as the mean + SD of three independent experiments (Mann-Whitney U test, Kruskal-Wallis, Tukey test). REST behaves like a tumor suppressor, decreasing the aggressiveness of 22rv1 cells, probably through the repression of EMT and the neuroendocrine phenotype. Furthermore, REST could represent a response marker to ENZ in PCa patients.
Keyphrases
- epithelial mesenchymal transition
- prostate cancer
- induced apoptosis
- mycobacterium tuberculosis
- cell cycle arrest
- transcription factor
- signaling pathway
- transforming growth factor
- radical prostatectomy
- stem cells
- endoplasmic reticulum stress
- cell proliferation
- cell therapy
- dna methylation
- long non coding rna
- newly diagnosed
- south africa
- ejection fraction
- genome wide
- prognostic factors
- pi k akt
- genome wide identification
- patient reported outcomes